RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Science 37 Holdings Stock

Science 37 Holdings P/S 2024

Science 37 Holdings P/S

10.4

Ticker

SNCE

ISIN

US8086441081

As of Nov 7, 2024, Science 37 Holdings's P/S ratio stood at 10.4, a 15.3% change from the 9.02 P/S ratio recorded in the previous year.

The Science 37 Holdings P/S history

Science 37 Holdings Aktienanalyse

What does Science 37 Holdings do?

Science 37 Holdings Inc. is a company specializing in clinical trials supported by technology and digital methods. It was founded in 2014 by a team of experienced medical and technological experts. The company is headquartered in Los Angeles, California, USA. Science 37's business model focuses on accelerating clinical trials and reducing costs by facilitating access to patients and data through a digital, telemedicine-based infrastructure. This is changing the way clinical trials are conducted by addressing one of the biggest obstacles to industrial development: the lengthy recruitment of patients. The various divisions of Science 37 include a platform for telemedicine studies, which allows virtual researchers to assess and connect with patients remotely, an in-house platform for clinical data management and analysis, and an extensive network of physicians and patients who offer and participate in clinical studies. Science 37's partners include pharmaceutical companies, biotech companies, academic institutions, and government agencies. Science 37 offers a wide range of products tailored to the specific needs of its customers. These products include: 1. NORA - A telemedicine platform for near-site recruitment, which allows patients to conveniently participate in a clinical trial through their own device. The platform provides a seamless and integrated experience for the patient and facilitates collaboration between study centers and virtual researchers. 2. NEST - A platform for clinical studies designed for the management of large data-driven studies. NEST provides a central database that simplifies the collection and management of study data and complies with compliance requirements. 3. SIV - A cloud-based platform for site initiation visits, which allows sponsors to accelerate study initiation with a wealth of site information without the need for an on-site visit. 4. Decentralized Clinical Trials - A fully digital platform that supports a clinical study from recruitment to data analysis and uses the "bring your own device" paradigm (BYOD). Decentralized Clinical Trials allow access from anywhere, whenever the patient desires. The company has an impressive track record, having worked on more than 27 clinical trials and being awarded numerous accolades, including "Most Innovative Clinical Trial Solution Provider" at the Global Health & Pharma (GHP) Awards 2019. Overall, Science 37 is an innovative company that has revolutionized the way clinical trials are conducted. Technology has the potential to radically transform medical research and accelerate drug development. Science 37 is pushing the boundaries of what is possible in large-scale patient recruitment and is a key player in the digital transformation of clinical research. Science 37 Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Science 37 Holdings's P/S Ratio

Science 37 Holdings's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Science 37 Holdings's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Science 37 Holdings's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Science 37 Holdings’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Science 37 Holdings stock

What is the price-to-earnings ratio of Science 37 Holdings?

The price-earnings ratio of Science 37 Holdings is currently 10.4.

How has the price-earnings ratio of Science 37 Holdings changed compared to last year?

The price-to-earnings ratio of Science 37 Holdings has increased by 15.3% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Science 37 Holdings high compared to other companies?

Yes, the price-to-earnings ratio of Science 37 Holdings is high compared to other companies.

How does an increase in the price-earnings ratio of Science 37 Holdings affect the company?

An increase in the price-earnings ratio of Science 37 Holdings would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Science 37 Holdings affect the company?

A decrease in the price-earnings ratio of Science 37 Holdings would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Science 37 Holdings?

Some factors that influence the price-earnings ratio of Science 37 Holdings are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Science 37 Holdings pay?

Over the past 12 months, Science 37 Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Science 37 Holdings is expected to pay a dividend of 0 USD.

What is the dividend yield of Science 37 Holdings?

The current dividend yield of Science 37 Holdings is .

When does Science 37 Holdings pay dividends?

Science 37 Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Science 37 Holdings?

Science 37 Holdings paid dividends every year for the past 0 years.

What is the dividend of Science 37 Holdings?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Science 37 Holdings located?

Science 37 Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von Science 37 Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Science 37 Holdings from 11/7/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/7/2024.

When did Science 37 Holdings pay the last dividend?

The last dividend was paid out on 11/7/2024.

What was the dividend of Science 37 Holdings in the year 2023?

In the year 2023, Science 37 Holdings distributed 0 USD as dividends.

In which currency does Science 37 Holdings pay out the dividend?

The dividends of Science 37 Holdings are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Science 37 Holdings

Our stock analysis for Science 37 Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Science 37 Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.